Development of novel therapies for Huntington's disease: hope and challenge.
Huntington's disease (HD) is an autosomal dominant neurological disease. It is a fatal neurological disorder affecting 5-10 out of 10,000 people. While there are intensive research efforts focusing on uncovering molecular mechanisms of the pathogenesis of HD, a number of studies have begun to look for effective therapies for HD. There is a large body of encouraging news on novel therapeutic developments. The present paper reviews drugs used for symptomatic treatment of HD and experimental therapies targeting HD molecular pathology.
Qin
Zheng-Hong
ZH
Department of Pharmacology, Soochow University School of Medicine, Suzhou 215007, China. zhqin5@hotmail.com
Wang
Jin
J
Gu
Zhen-Lun
ZL
D000547:Amantadine / Q000627:therapeutic use; D000818:Animals; D017690:Cell Transplantation; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D006801:Humans; D000071058:Huntingtin Protein; D006816:Huntington Disease / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D009154:Mutation; D017072:Neostriatum / Q000166:cytology; D009419:Nerve Tissue Proteins / Q000235:genetics*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009687:Nuclear Proteins / Q000235:genetics*; D019782:Riluzole / Q000627:therapeutic use
D004365:Drugs, Chinese Herbal; C086055:HTT protein, human; D000071058:Huntingtin Protein; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D009687:Nuclear Proteins; D019782:Riluzole; D000547:Amantadine